Abstract: Objective To evaluate the efficacy and toxicity of apatinib mesylate as third-line or above treatment for patients with advanced gastric adenocarcinoma.
Methods The clinical data of 20 patients with advanced gastric adenocarcinoma who failed at least two lines of prior chemotherapy from Dec 2014 to Jan 2016 were retrospectively analyzed. All patients received oral apatinib mesylate 500 mg perday until disease progression or intolerable toxicity. Results The response rate（RR）and disease control rate（DCR）was 10.0％ and 40.0％，respectively. The median progression free survival（PFS）and median overall survival（OS）were 2.7 months and 4.3 months， respectively. Apatinib treatment was well tolerated without severe toxicities；the common adverse events were grade 1 to 3 hypertension，hand-foot syndrome and proteinuria. Conclusion Apatinib mesylate is effective and tolerable for patients with advanced gastric adenocarcinoma who failed second-line or obove chemotherapy.